You're Not Alone in Your Treatment Journey

  • About GAMMAGARD LIQUID Treatment

    GAMMAGARD LIQUID is a ready-to-use liquid medicine that contains immunoglobulin G, or IgG, antibodies, which protect the body against infection. These antibodies, collected from the plasma of healthy people, replace the missing antibodies in primary immunodeficiency (PI) patients. GAMMAGARD LIQUID is used to treat PI in people 2 years and older.1

    GAMMAGARD LIQUID temporarily increases the amount of antibodies in your body to fight bacteria, viruses, or other foreign bodies.1

    GAMMAGARD LIQUID offers a choice of intravenous (IV) and subcutaneous (SubQ) administration options, and can be infused either directly into a vein (IV) or just under the skin into the fatty tissue (SubQ). Talk to your healthcare provider about the treatment administration option that may be best for you.

    Reference: 1. GAMMAGARD LIQUID [Immune Globulin Infusion (Human)] 10% [Prescribing Information]. Westlake Village, CA: Baxalta US Inc.


      Intravenous (IV) administration goes into a vein. Find out more about what it means for you.
      Learn About IV

      Subcutaneous (SubQ) administration goes under the skin. See if this option might be right for you.
      Learn About SubQ
    • Choosing What's Best for You

      Understand the differences between IV and SubQ administration.
      See Your Options

      Get answers to frequently asked questions about administration, insurance, and more.
      Find Your Answers

Gammagard Liquid MyIgCoPayCard Program Terms and Conditions

This manufacturer's coupon program is not valid for prescriptions reimbursed, in whole or in part, by Medicaid, Medicare, Medigap, VA, DoD, TRICARE, or any other federal or state healthcare programs, including state pharmaceutical assistance programs, and where prohibited by the health insurance provider or by law

Shire's MyIgCoPayCard program provides a maximum total benefit of $5,000 for eligible out-of-pocket costs and expires 12 months from date of activation. Eligible costs include deductible, copayment, and co-insurance costs for eligible Shire IG (Immunoglobulin) products. Non-medication expenses, such as ancillary supplies or administration-related costs, are not eligible.

To be eligible, patients must: 1. be starting or receiving treatment with (and have current prescription for) an eligible Shire IG product with an ICD-10 for a diagnosis of Primary Immunodeficiency; and 2. have commercial insurance that covers medication costs for prescribed Shire IG product and allows for CoPay assistance; and 3. be two (2) years old or older.

Acceptance of this offer must be consistent with the terms of benefits provided by patient's health insurance provider.

Offer limited to one card per person and may not be combined with any other coupon, discount, prescription savings card, rebate, free trial, patient assistance, or other offer.

This program is only valid for residents of the United States.

Shire reserves the right to change or discontinue this program at any time without notice.

This is not health insurance.


Add to patient instructions:

If your insurance situation changes, it is your responsibility to notify MyIgSource's CoPay assistance program.

© 2017 Shire. All rights reserved.

SHIRE and the Shire Logo are registered trademarks of Shire Pharmaceutical Holdings Ireland Limited or its affiliates. Gammagard Liquid is a trademark or registered trademark of Baxalta Incorporated, a wholly owned, indirect subsidiary of Shire plc.

S30515 04/17

Please expand for Indication and Important Safety Information.


What is the most important information that I should know about GAMMAGARD LIQUID?

GAMMAGARD LIQUID can cause the following serious reactions: severe allergic reactions causing difficulty in breathing or skin rashes; decreased kidney function or kidney failure; blood clots in the heart, brain, lungs or elsewhere in the body; severe headache, drowsiness, fever, painful eye movements, or nausea and vomiting; dark colored urine, swelling, fatigue, or difficulty breathing.